Vertex Pharmaceuticals Incorporated ( NASDAQ: VRTX) American Diabetes Association (ADA) 85th Scientific Sessions Conference June 20, 2025 8:15 PM ET James Markmann - Corporate Participant Michael ...

A once-weekly basal insulin had similar safety and efficacy to a daily insulin option, a series of trials from the phase III ...

An investigational, oral small-molecule GLP-1 receptor agonist improved glycated hemoglobin levels in adults with early-stage ...

CHICAGO -- Adding investigational cagrilintide to a GLP-1 receptor agonist increased weight loss in adults with obesity with ...

The combination of once-weekly cagrilintide 2.4 mg and semaglutide 2.4 mg conferred greater weight loss at 68 weeks compared ...

Most in a small group of patients receiving a stem cell-based infusion no longer needed insulin, but the drug may not suit those with more manageable type 1 diabetes.

CHICAGO, June 22, 2025 /PRNewswire/ -- Today, a new study demonstrates inhaled insulin as a safe and effective replacement for rapid-acting meal insulin in children with type 1 diabetes. Results from ...

Semaglutide 1 mg improves walking distance in patients with early peripheral artery disease and type 2 diabetes, regardless ...

Endogenex today reported positive findings from studies of its endoscopic procedure aimed at transforming diabetes care.